Alzamend Neuro, Inc. (ALZN:NASDAQ) closed at $1.13 on October 23, 2026, up 0.89% on the day. The stock trades 57.8% below its 52-week high of $2.68 and 34.5% above its 52-week low of $0.840. Over the past year, it lost 54.6%. Alzamend Neuro, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, ALZN closed higher on 109 days (43%). Its best day was May 20, 2026 (+18.81%) and its worst was March 27, 2026 (-30.00%). The stock moved 10% or more in a single session 13 times. It opened at least 5% above the previous day's high 4 times.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline of product candidates consist of two novel therapeutic drug candidates namely AL001 a patented ionic co-crystal technology delivering a therapeutic combination of lithium, proline and salicylate, and; AL002 a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that reduces beta-amyloid plaque and seeks to restore the ability of the patient's immunological system to combat Alzheimer's.
Find more stocks like ALZN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.